News

Rogers Corporation Reports Third Quarter 2026 Results

Fintel·17:42ROG▲+5.0%

Rogers Corporation (ROG) Q3 2026 Earnings Call Transcript

SeekingAlpha·15:29ROG▲+5.0%

Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre. With a planned menu of over 100 high-medical-value assays, and reaction times of 18 minutes or less for more than 90% of tests, the platform allows smaller laboratories to bring testing in-house, reducing turnaround times for patients.1,2,3 The cobas smart e uses the same reagents and Elecs

Yahoo·02:00

Rogers (ROG) to report earnings tomorrow: here is what to expect

Engineered materials manufacturer Rogers (NYSE:ROG) will be reporting results this Tuesday afternoon. Here’s what to look for.

Yahoo·00:54ROG▲+5.0%

Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly l

Yahoo·11:30

Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)

Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups1As the first antisense oligonucleotide (ASO) evaluated in IgAN, sefaxersen inhibits complement factor B production and has the potential to slow IgAN disease progression by reducing kidney inflammation2Investigational sefaxersen is intended to be a once-monthly subcutaneous inj

Yahoo·13:30

B. Riley Securities Maintains Buy on Rogers, Lowers Price Target to $195

B. Riley Securities analyst Craig Ellis maintains Rogers (NYSE:ROG) with a Buy and lowers the price target from $225 to $195.

Benzinga·08:52ROG▲+5.0%

[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine […]

Ad hoc announcement pursuant to Art. 53 LRBasel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 Group sales were +6% at constant exchange rates (CER)1, +1% when reported in CHF and +7% in USD2, in the first nine months of 2026, driven by high demand for our innovative medicines and diagnostics. In the third quarter, sales gre

Yahoo·01:00

Roche presents new pivotal trial data across broad neuroimmunology portfolio at MSToronto2026

Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS)Fenebrutinib FENhance 1 & 2 Phase III pooled data show a 55% reduction in annualised relapse rate (ARR) vs active comparatorFollowing European Commission paediatric approval on 15 October, new Ocrevus OPERETTA 2 Phase III data show 90% of children aged 10–17 remained relapse-free over two

Yahoo·08:00

Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio

Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancerPatient-reported outcomes from phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancerPhase III results in Chinese patients with metastatic naso

Yahoo·01:00

FDA approves Roche’s Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration1,2 Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home SC treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered1 Enspryn

Yahoo·01:00

Rogers Corporation Schedules Third Quarter 2026 Earnings Call for October 27

CHANDLER, Ariz., October 13, 2026--Rogers Corporation (NYSE: ROG) ("Rogers") will announce third quarter 2026 results after market close on October 27, 2026. The company will hold a conference call at 5:00 pm ET to discuss the results. The call will be hosted by Ali El-Haj, President and Chief Executive Officer, who will be joined by Laura Russell, Senior Vice President and Chief Financial Officer.

Yahoo·16:05ROG▲+5.0%

Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary extrahepatic delivery platform.

Yahoo·03:00

Roche presents new Phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss

In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks1,2UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated3,4The FDA has accepted Roche's Biologics License Application (BLA), with an approval decision expected by July 2027 Basel, 10 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today n

Yahoo·17:40

FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer

FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone1First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III

Yahoo·01:00